Phase 3B study assessing SOF/RBV and SOF/PEG/RBV for Genotype 2 or 3 C

• Research type

  Research Study

• Full title

  A Phase 3B Randomized, Open-Label Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection

• IRAS ID

  136890

• Contact name

  Graham Foster

• Contact email

  g.r.foster@qmul.ac.uk

• Sponsor organisation

  Gilead Sciences Inc.

• Eudract number

  2013-002641-11

• ISRCTN Number

  n/a

• REC name

  East of England - Cambridge South Research Ethics Committee

• REC reference

  13/EE/0276

• Date of REC Opinion

  7 Oct 2013

• REC opinion

  Further Information Favourable Opinion